Drug intelligence / Profile preview

bizelesin

Development stage: Phase 1
Lead developer: Pfizer
Modality: Small Molecules
Administration: Intravenous

Overview

Bizelesin is a synthetic cyclopropylpyrroloindole antineoplastic antibiotic and small molecule that acts as a bifunctional DNA alkylating agent. It binds to the minor groove of DNA, inducing interstrand cross-linking, which inhibits both DNA replication and RNA synthesis. This leads to cell cycle arrest at the G2/M phase and can result in cellular senescence without apoptosis. Bizelesin was initially developed by Pfizer for use in cancer therapy, particularly for advanced solid tumors, but its clinical development was discontinued after early-phase trials[1][3][4][5].

Other names: Bizelesina

Targets

dsDNA-specific BCR (Double-stranded DNA-specific B-cell receptor)

Beyond the preview

Go deeper on bizelesin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bizelesin.

Explore the full profile